Appili Therapeutics widens six-month loss to C$3.5M with thin cash
Per TradingView, Appili Therapeutics posted a C$3.5M net loss for the six months to September 30, 2026, up C$1.3M, with cash of just C$0.4M.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Appili Therapeutics reported a net loss of C$3.5M for the six months ended September 30, 2026. That is C$1.3M more than the C$2.2M loss in the same period a year earlier. According to TradingView, cash stood at C$0.4M on September 30, compared with C$0.04M on March 31, 2026.
Bloom Burton provided C$1.2M in advances over the six months, but the company says these have no specific payment terms. Repayment deadlines owed to lenders were extended to November 30 and December 31. After the period, three employees were laid off and the chief development officer stepped down.
why it matters
Losses are growing while cash remains limited against ongoing development costs, and near-term repayment deadlines add refinancing risk. The approval timeline for ATI-1801 depends on securing funding, so it remains uncertain.
tags
instruments
sources
- Appili Therapeutics Inc. (APLI) Reports $3.5M Six-Month Loss, Up $1.3M — TradingView, 13 November 2026 at 01:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗